Loading...
Some clinical data have suggested that higher vancomycin MICs may correlate with suboptimal treatment response in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. To investigate this situation, researchers in New York (funded by the manufacturer of daptomycin) conducted a retrospective cohort study involving 92 adults with MRSA bacteremia who were treated with vancomycin. Twenty-eight of the patients suffered treatment failure, defined as all-cause mortality within 30 days (16 patients), positive blood cultures after ≥10 days of therapy (6 patients), or recurrence of bacteremia within 60 days after stopping vancomycin (12 patients). Among these patients, five met two of the criteria, and one met all three.
Compare…